Dr. Vivi Ziv, Analyst Research Laboratories’ CEO, has been invited to join BGN Technologies patent committee, as a representative of the biomedical industry.  

BGN Technologies is the technology transfer company of Ben-Gurion University of the Negev, Israel, which is one of Israel’s leading research universities and among the world leaders in many fields.

BGN Technologies, which is responsible for the University’s patent portfolio, initiates, leads and implements collaborations with institutions and companies and world-wide, and attracts strategic partners and investors in the fields of hi-tech, life science, cleantech and more.

BGN Technologies’ patent committee is responsible for determining which of the University’s patents, that are about to complete their provisional patent stage, will continue to be supported by the University.

The combination of Analyst’s decades of experience in the biomedical industry, with Dr. Ziv’s experience of more than 23 years in the pharmaceutical, biotechnology and medical device industries, present unique capabilities of a broad industry overview.

Dr. Ziv, Analyst’s CEO said: “I am extremely honored to join this committee and support the decision-making process of such critical issues. This is in line with Analyst’s and our parent company, Tentamus, on-going commitment to support the industry we service, especially the young, early-stage companies.”

About BGN Technologies

BGN Technologies is the technology company of Ben-Gurion University of the Negev, Israel. The company brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchers and students. To date, BGN Technologies has established over 100 startup companies in the fields of biotech, hi-tech, and cleantech as well as initiating leading technology hubs, incubators, and accelerators. Over the past decade, it has focused on creating long-term partnerships with multinational corporations such as Deutsche Telekom, Dell-EMC, IBM, PayPal, Cincinnati Children’s Medical Center, Merck, Sigma and Bayer, securing value and growth for Ben-Gurion University as well as for the Negev region. For more information, visit the BGN Technologies website.

About Analyst Research Laboratories

Analyst Research Laboratories is a GMP, GLP and GCLP accredited, FDA-inspected contract lab. The 1,000sqm modern lab specializes in all aspects of analysis of pharmaceuticals, providing a multitude of Analytical & Bioanalytical services to the pharmaceutical, medical cannabis, biotech and medical device industries. Please visit Analyst’s website for further information at https://www.analyst-labs.com

Über die Tentamus Group GmbH

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
https://www.tentamus.com

Ansprechpartner:
Vivi Ziv
CEO Analyst Research Laboratories
E-Mail: vivi@analyst-labs.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel